CoagulationDisorders near Wesley Chapel, FL

Care Philosophy: Dr Jaglal completed his hematology/oncology fellowship at the University of South Florida and Moffitt Cancer Center. His research interests are in benign hematologic disorders: hemophilia, von Willebrand's disease, anemias, hemostasis and thrombosis disorders. Clinically, Dr Jaglal is a hematologist/oncologist and member of Moffitt Medical Group in the Satellite and Community Oncology Department practicing at Tampa General Hospital and Moffitt international Plaza. The MMG faculty at TGH provides invaluable oncology services to the large patient population of this leading regional hospital.

Care Philosophy: Dr David Sallman is an Assistant Member in the Department of Malignant Hematology at Moffitt Cancer Center. Dr Sallman's clinical interests are myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). Dr Sallman earned his MD degree from the University of South Florida College of Medicine. He completed an Internal Medicine Residency at Massachusetts General Hospital and, most recently, a Hematology/Oncology Fellowship at Moffitt Cancer Center.

Care Philosophy: Dr Pinilla-Ibarz has been at Moffitt since 2006 and holds the rank of Senior Member and Head of Lymphoma Section in the Department of Malignant Hematology. Dr Pinilla-Ibarz received the 2016-17 Moffitt Physician of the Year Award. He was also the recipient of the ASCO young investigator award in 2003 and the ASCO career development award in 2007. Dr Pinilla-Ibarz is nationally and internationally known for his expertise in chronic leukemia and he currently has over 120 peer-reviewed publications. He has received grant support through the Leukemia & Lymphoma Society and also from multiple industry partners. His clinical interests include chronic myeloid leukemia and chronic lymphoid leukemia.

Care Philosophy: Dr Rachid Baz is a board-certified hematologist and medical oncologist who came to Moffitt in 2008 from Cleveland Clinic. Currently, Dr Baz is the Myeloma Section Head in the Department of Malignant Hematology at Moffitt Cancer Center and co-Director of the Pentecost Family Myeloma Research Center. He has developed a special expertise in managing patients with plasma cell disorders such as multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), plasmacytoma, primary systematic amyloidosis, and Waldenstrom's macroglobulinemia (WM). Among other awards, he was the recipient of the Junior Clinical Science Award at Moffitt, and the University of South Florida Outstanding Resident Teaching Award.

Care Philosophy: At Florida Cancer Specialists & Research Institute you will find experienced and compassionate doctors you can trust to treat your unique cancer. Our physicians share a passion for delivering exceptional and personalized care for all forms of cancer and blood disorders, close to home. From genetic screening to immunotherapies and access to clinical trials, our top-ranked cancer experts provide the newest and most advanced treatments available increasing cure rates and extending lives. No other community-based oncology practice in Florida matches the clinical trial opportunities we offer. The majority of new cancer drugs approved for use in the U.S. in recent years were studied in clinical trials with FCS participation, prior to approval. Every interaction is focused on each patients experience and well-being to minimize disruption to daily life. Beginning with your first appointment, our dedicated FCS team provides expert guidance and support at every step of your cancer journey.

Care Philosophy: Gustavo Rivero, MD, is a dual fellowship-trained hematology and medical oncologist specializing in the treatment of acute and chronic leukemia. Dr Riveros areas of clinical expertise includes: acute and chronic myeloid leukemias, acute lymphoid leukemias, myelodysplastic syndrome, myeloproliferative neoplasm, and clonal hematopoiesis of indetermined potential (CHIP).

Care Philosophy: Dr Bijal Shah is an Associate Member in the Department of Malignant Hematology. Dr Shah's primary clinical interests are in Non-Hodgkin Lymphomas (particularly mantle cell lymphoma) and Acute Lymphoblastic Leukemia. As an internist and pediatrician, Dr Shah also has a special interest in adolescent and young adult malignant hematology.

Care Philosophy: Dr Michael Jain is an Associate Member and ICE-T Medical Director in the Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy. Dr Jain earned his MD and PhD at McGill University in Montrv©al, in the province of Quv©bec, Canada. His PhD in Cell Biology was completed under the supervision of Dr John Bergeron. Dr Jain completed an Internal Medicine Residency and a Hematology Residency at the University of Toronto. He completed a Clinician Scientist Training Program and Clinical Fellowship in Lymphoma and Autologous Stem Cell Transplantation at Princess Margaret Cancer Center, University of Toronto.

Care Philosophy: Dr Ochoa-Bayona's interests are in traditional bone marrow transplant using high dose chemotherapy and autologous or allogeneic stem transplant to treat myeloma, lymphoma, advanced or recurrent germ cell tumors of the ovary and testis despite standard chemotherapy, myelodysplastic syndromes, acute and chronic leukemias. He completed his training in Internal Medicine, Hematology/Medical Oncology and Hematopoietic Stem Cell Transplantation from the University of Texas Health Science Center at San Antonio in 2002.

Care Philosophy: Dr Bejanyan is an Associate Member, Program Leader of Blood and Marrow Transplant (BMT) and Head of the Leukemia/Myeloid Section of the BMT and Cellular Immunotherapy Department at Moffitt Cancer Center. She is an Associate Professor in Oncologic Sciences at the University of South Florida.Dr Bejanyan also served as the Clinical Scientific Co-Director of Moffitt Pharmacokinetics and Pharmacodynamics Core. As a physician investigator with clinical and research expertise in BMT and cellular immunotherapies for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), Dr Bejanyan focuses in advancing clinical and translational research by fostering innovative immune cell therapy strategies to treat leukemia.